显微镜下血尿初始评估阴性后的泌尿系恶性肿瘤相对风险:8465例长期人群回顾性分析
该研究基于人群回顾性分析8465例显微镜下血尿且膀胱镜与CT尿路造影初始评估阴性的成人,按年龄、性别和吸烟状态匹配8465例对照。结果显示两组泌尿系恶性肿瘤发生率无统计学差异(0.74% vs 0.83%,p=0.54),后续出现肉眼血尿显著增加癌症风险(男性OR 2.35,女性OR 4.25)。结论认为初始评估阴性的显微镜下血尿患者后续泌尿系恶性肿瘤率低于1%,除非出现肉眼血尿,否则可能无需进一步泌尿系评估。
要点
- 初始膀胱镜和CT尿路造影阴性的显微镜下血尿患者,后续泌尿系恶性肿瘤率低于1%。
- 随访中出现肉眼血尿显著增加泌尿系恶性肿瘤风险,男性OR 2.35、女性OR 4.25。
- 无额外血尿的男性后续癌症风险降低(OR 0.32),女性无额外血尿者风险未显著增加。
局限性
- 回顾性研究设计,依赖ICD编码识别病例和结局,可能存在编码偏倚。
- 原文未报告多中心或单中心信息,外推性需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To evaluate whether microscopic hematuria (MH) patients with a negative initial evaluation have an elevated risk for urinary carcinoma.
METHODS: This is a population-based retrospective study with a matched control identified 8465 adults with an MH ICD code, an initial negative urinary malignancy work-up of cystoscopy and CT urography, and at least 35 months of clinical care. 8465 hematuria naïve controls were age, gender, and smoking status matched. Subsequent coding of non-prostatic urinary cancer, or any following hematuria codes: additional microscopic unspecified or unspecified hematuria, and gross hematuria was obtained. Χ2 tests were performed.
RESULTS: There was no statistically significant difference in urinary malignancy rates (p > 0.05). Any urinary cancer: cases 0.74% (63/8465; 95% CI 0.58-0.95%)/controls 0.83% (71/8465; 95% CI 0.66-1.04%%) (p = 0.54); bladder: 0.45%/0.47% (p = 0.82); renal: 0.31%/0.38% (p = 0.43); ureteral: 0.01%/0.02% (p = 0.56). Subsequent gross hematuria in both males and females increased the odds of cancer: males 2.35 (p = 0.001; CI 1.42-3.91); females 4.25 (p < 0.001; CI 1.94-9.34). Males without additional hematuria had decreased odds ratio: 0.32 (p = 0.001; CI 0.16-0.64). Females without additional hematuria 0.58 (p = 0.19; CI 0.26-1.30) and both genders with additional unspecified hematuria/microscopic hematuria males 1.02 (p = 0.97; CI 0.50-2.08) and females 1.00 (p = 0.99; CI 0.38-2.66) did not have increased odds ratios (p > 0.05).
CONCLUSION: MH patients with initial negative evaluation have a subsequent urologic malignancy rate of less than 1% and likely do not need further urinary evaluation unless they develop gross hematuria.
引用
- Lisanti, Graeber, Syed, et al. What is the relative risk of urologic malignancy in microscopic hematuria patients after negative evaluation? A long-term population-based retrospective analysis of 8465 patients. Abdom Radiol (NY). 2023. PMID: 36592198. doi:10.1007/s00261-022-03793-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。